{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:48:51Z","timestamp":1791643731302,"version":"4.3.4"},"reference-count":212,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004386","name":"Universiti Malaya","doi-asserted-by":"publisher","award":["BKP042-2025-ECRG"],"award-info":[{"award-number":["BKP042-2025-ECRG"]}],"id":[{"id":"10.13039\/501100004386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Brain cancer is one of the most challenging malignancies and a major contributor to worldwide morbidity and mortality. Glioblastoma, the most aggressive adult brain tumor, is associated with poor prognosis despite conventional therapies such as surgery, chemotherapy, and radiotherapy, which often result in severe toxicity and long-term side effects. Immunotherapy holds the potential to provide durable and specific anti-tumor responses; however, its success in brain cancer is hindered by obstacles such as the blood-brain barrier, immunosuppressive tumor microenvironment, and tumor heterogeneity. Nanomedicine offers a powerful approach to overcoming these barriers through targeted and efficient drug delivery. Nanotechnology-based platforms, including lipid-based, polymeric, and inorganic nanoparticles, have demonstrated superior therapeutic efficacy compared to free drugs, with several formulations advancing into clinical trials. Among these, nanotechnology-enabled vaccines represent an emerging frontier, capable of enhancing antigen presentation, stimulating strong immune responses, and overcoming tumor-induced immunosuppression. By combining the precision of nanocarriers with the long-lasting protection of vaccines, nano-vaccines hold great potential to transform brain cancer immunotherapy. Recent studies also suggest that integrating artificial intelligence (AI) with nanotechnology could further enhance the design, targeting, and effectiveness of immunotherapies. Moreover, AI is revolutionizing treatment development by enabling the prediction of immunogenicity, immune responses, and optimizing formulation design and dosing strategies. These advancements collectively accelerate the development and enhance the precision and efficiency of immunotherapy. Hence, this review discusses current nanotechnology-based immunotherapies and highlights the emerging role of integrating AI in vaccine development as next-generation strategies for improving outcomes in brain cancer treatment.<\/jats:p>","DOI":"10.1186\/s43046-026-00394-3","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:47:54Z","timestamp":1787071674000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nanotechnology-based immunotherapy: integrating Artificial Intelligence (AI) with current strategies in combating brain cancer disease"],"prefix":"10.1186","volume":"38","author":[{"given":"Alia Syazana Mohd","family":"Roslei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasniza Zaman","family":"Huri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyah Ayu Oktavianie A.","family":"Pratama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Khusairi","family":"Azemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulhisyam Abdul","family":"Kari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Yasin","family":"Ina-Salwany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najihah Mohd","family":"Hashim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Faizal","family":"Ghazali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdin Shakirin Mohamad","family":"Norpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Fauzi Abd","family":"Jalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"AlGhenaimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazlan","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Luqman","family":"Nordin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"394_CR1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.ncl.2016.06.014","volume":"34","author":"KA McNeill","year":"2016","unstructured":"McNeill KA. Epidemiology of brain tumors. Neurol Clin. 2016;34:981\u201398. https:\/\/doi.org\/10.1016\/j.ncl.2016.06.014.","journal-title":"Neurol Clin"},{"key":"394_CR2","doi-asserted-by":"publisher","first-page":"e18222","DOI":"10.1016\/j.heliyon.2023.e18222","volume":"9","author":"I Ilic","year":"2023","unstructured":"Ilic I, Ilic M. International patterns and trends in the brain cancer incidence and mortality: an observational study based on the global burden of disease. Heliyon. 2023;9:e18222. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e18222.","journal-title":"Heliyon"},{"key":"394_CR3","doi-asserted-by":"publisher","first-page":"21936","DOI":"10.1038\/s41598-024-73277-z","volume":"14","author":"SE Mousavi","year":"2024","unstructured":"Mousavi SE, Seyedmirzaei H, Shahrokhi Nejad S, Nejadghaderi SA. Epidemiology and socioeconomic correlates of brain and central nervous system cancers in Asia in 2020 and their projection to 2040. Sci Rep. 2024;14:21936. https:\/\/doi.org\/10.1038\/s41598-024-73277-z.","journal-title":"Sci Rep"},{"key":"394_CR4","doi-asserted-by":"publisher","first-page":"112119","DOI":"10.1016\/j.biopha.2021.112119","volume":"143","author":"S Rasheed","year":"2021","unstructured":"Rasheed S, Rehman K, Akash MSH. An insight into the risk factors of brain tumors and their therapeutic interventions. Biomed Pharmacother. 2021;143:112119. https:\/\/doi.org\/10.1016\/j.biopha.2021.112119.","journal-title":"Biomed Pharmacother"},{"key":"394_CR5","doi-asserted-by":"publisher","unstructured":"Kaid C, Sherwood M, Mitsugi T, Zatz M. Zika virus as an oncolytic therapy against brain tumors. Zika Virus Biology, Transmission, and Pathology, Elsevier. 2021:327\u201338. https:\/\/doi.org\/10.1016\/B978-0-12-820268-5.00030-4.","DOI":"10.1016\/B978-0-12-820268-5.00030-4"},{"key":"394_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/B978-0-12-824535-4.00011-2","volume":"191","author":"NE Tobias Walbert","year":"2023","unstructured":"Tobias Walbert NE, Stec. Palliative care in brain tumors. Handb Clin Neurol. 2023;191:69\u201380. https:\/\/doi.org\/10.1016\/B978-0-12-824535-4.00011-2.","journal-title":"Handb Clin Neurol"},{"key":"394_CR7","doi-asserted-by":"publisher","first-page":"108108","DOI":"10.1016\/j.pharmthera.2022.108108","volume":"236","author":"J Yu","year":"2022","unstructured":"Yu J, Mu Q, Fung M, Xu X, Zhu L, Ho RJY. Challenges and opportunities in metastatic breast cancer treatments: nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response. Pharmacol Ther. 2022;236:108108. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108108.","journal-title":"Pharmacol Ther"},{"key":"394_CR8","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.3390\/ijms23052607","volume":"23","author":"Y Esemen","year":"2022","unstructured":"Esemen Y, Awan M, Parwez R, Baig A, Rahman S, Masala I, et al. Molecular pathogenesis of glioblastoma in adults and future perspectives: a systematic review. Int J Mol Sci. 2022;23:2607. https:\/\/doi.org\/10.3390\/ijms23052607.","journal-title":"Int J Mol Sci"},{"key":"394_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13046-021-02017-2","volume":"40","author":"J De Waele","year":"2021","unstructured":"De Waele J, Verhezen T, van der Heijden S, Berneman ZN, Peeters M, Lardon F, et al. A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy. J Experimental Clin Cancer Res. 2021;40:213. https:\/\/doi.org\/10.1186\/s13046-021-02017-2.","journal-title":"J Experimental Clin Cancer Res"},{"key":"394_CR10","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1007\/s13346-021-01039-9","volume":"11","author":"CP Carney","year":"2021","unstructured":"Carney CP, Pandey N, Kapur A, Woodworth GF, Winkles JA, Kim AJ. Harnessing nanomedicine for enhanced immunotherapy for breast cancer brain metastases. Drug Deliv Transl Res. 2021;11:2344\u201370. https:\/\/doi.org\/10.1007\/s13346-021-01039-9.","journal-title":"Drug Deliv Transl Res"},{"key":"394_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175\u201396. https:\/\/doi.org\/10.1038\/s41573-018-0006-z.","journal-title":"Nat Rev Drug Discov"},{"key":"394_CR12","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3390\/cells12172159","volume":"12","author":"M Kaczmarek","year":"2023","unstructured":"Kaczmarek M, Pozna\u0144ska J, Fechner F, Michalska N, Paszkowska S, Napiera\u0142a A, et al. Cancer vaccine therapeutics: limitations and effectiveness\u2014a literature review. Cells. 2023;12:2159. https:\/\/doi.org\/10.3390\/cells12172159.","journal-title":"Literature Rev Cells"},{"key":"394_CR13","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhou F, Ali H, Lathia JD, Chen P. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cell Mol Immunol. 2024;21:1354\u201375. https:\/\/doi.org\/10.1038\/s41423-024-01226-x.","journal-title":"Cell Mol Immunol"},{"key":"394_CR14","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3390\/pharmaceutics12111085","volume":"12","author":"H Luo","year":"2020","unstructured":"Luo H, Shusta EV. Blood\u2013brain barrier modulation to improve glioma drug delivery. Pharmaceutics. 2020;12:1085. https:\/\/doi.org\/10.3390\/pharmaceutics12111085.","journal-title":"Pharmaceutics"},{"key":"394_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3390\/ph17020169","volume":"17","author":"IN Khan","year":"2024","unstructured":"Khan IN, Navaid S, Waqar W, Hussein D, Ullah N, Khan MUA, et al. Chitosan-based polymeric nanoparticles as an efficient gene delivery system to cross blood brain barrier: in vitro and in vivo evaluations. Pharmaceuticals. 2024;17:169. https:\/\/doi.org\/10.3390\/ph17020169.","journal-title":"Pharmaceuticals"},{"key":"394_CR16","doi-asserted-by":"publisher","unstructured":"Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020;7. https:\/\/doi.org\/10.3389\/fmolb.2020.00193.","DOI":"10.3389\/fmolb.2020.00193"},{"key":"394_CR17","doi-asserted-by":"publisher","unstructured":"Bor G, Hosta-Rigau L. Next generation of brain cancer nanomedicines to overcome the Blood\u2013Brain Barrier (BBB): insights on transcytosis, perivascular tumor growth, and BBB models. Adv Ther (Weinh). 2023;6. https:\/\/doi.org\/10.1002\/adtp.202300161.","DOI":"10.1002\/adtp.202300161"},{"key":"394_CR18","doi-asserted-by":"publisher","first-page":"126096","DOI":"10.1016\/j.ijpharm.2025.126096","volume":"684","author":"Y Bahrami","year":"2025","unstructured":"Bahrami Y, Bolideei M, Mohammadzadeh S, Gahrouei RB, Mohebbi E, Haider KH, et al. Applications of artificial intelligence and nanotechnology in vaccine development. Int J Pharm. 2025;684:126096. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.126096.","journal-title":"Int J Pharm"},{"key":"394_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.20471\/acc.2021.60.03.06","volume":"60","author":"N Koruga","year":"2022","unstructured":"Koruga N, Pekmezovi\u0107 T, Toma\u0161 I, Soldo Koruga A, Butkovi\u0107 Soldo S, U\u017earevi\u0107 Z, et al. Factors affecting outcome in the treatment of glioblastoma. Acta Clin Croat. 2022;60:373\u20138. https:\/\/doi.org\/10.20471\/acc.2021.60.03.06.","journal-title":"Acta Clin Croat"},{"key":"394_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/cancers17010146","volume":"17","author":"D Sipos","year":"2025","unstructured":"Sipos D, Raposa BL, Freihat O, Simon M, Mekis N, Cornacchione P, et al. Glioblastoma: clinical presentation, multidisciplinary management, and long-term outcomes. Cancers (Basel). 2025;17:146. https:\/\/doi.org\/10.3390\/cancers17010146.","journal-title":"Cancers (Basel)"},{"key":"394_CR21","doi-asserted-by":"publisher","first-page":"109821","DOI":"10.1016\/j.biopha.2020.109821","volume":"124","author":"S Tan","year":"2020","unstructured":"Tan S, Li D, Zhu X. Cancer immunotherapy: pros, cons and beyond. Biomed Pharmacother. 2020;124:109821. https:\/\/doi.org\/10.1016\/j.biopha.2020.109821.","journal-title":"Biomed Pharmacother"},{"key":"394_CR22","doi-asserted-by":"publisher","first-page":"H1","DOI":"10.1530\/VB-19-0033","volume":"2","author":"L Marchetti","year":"2020","unstructured":"Marchetti L, Engelhardt B. Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation. Vascular Biology. 2020;2:H1\u201318. https:\/\/doi.org\/10.1530\/VB-19-0033.","journal-title":"Vascular Biology"},{"key":"394_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11864-018-0576-3","volume":"19","author":"LB Hoang-Minh","year":"2018","unstructured":"Hoang-Minh LB, Mitchell DA. Immunotherapy for brain tumors. Curr Treat Options Oncol. 2018;19:60. https:\/\/doi.org\/10.1007\/s11864-018-0576-3.","journal-title":"Curr Treat Options Oncol"},{"key":"394_CR24","doi-asserted-by":"publisher","unstructured":"Belykh E, Shaffer KV, Lin C, Byvaltsev VA, Preul MC, Chen L. Blood-brain barrier, blood-brain tumor barrier, and fluorescence-guided neurosurgical oncology: delivering optical labels to brain tumors. Front Oncol. 2020;10. https:\/\/doi.org\/10.3389\/fonc.2020.00739.","DOI":"10.3389\/fonc.2020.00739"},{"key":"394_CR25","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3390\/curroncol29020075","volume":"29","author":"S Cozzi","year":"2022","unstructured":"Cozzi S, Najafi M, Gomar M, Ciammella P, Iotti C, Iaccarino C, et al. Delayed effect of dendritic cells vaccination on survival in glioblastoma: a systematic review and meta-analysis. Curr Oncol. 2022;29:881\u201391. https:\/\/doi.org\/10.3390\/curroncol29020075.","journal-title":"Curr Oncol"},{"key":"394_CR26","doi-asserted-by":"publisher","unstructured":"Sharma A, Campbell M, Yee C, Goswami S, Sharma P. Immunotherapy of cancer. Clin Immunol. 2019;1033\u201348 .e1. https:\/\/doi.org\/10.1016\/B978-0-7020-6896-6.00077-6.","DOI":"10.1016\/B978-0-7020-6896-6.00077-6"},{"key":"394_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349. https:\/\/doi.org\/10.1146\/annurev-pathol-042020-042741.","journal-title":"Annu Rev Pathol"},{"key":"394_CR28","doi-asserted-by":"publisher","first-page":"116789","DOI":"10.1016\/j.bcp.2025.116789","volume":"233","author":"J Liu","year":"2025","unstructured":"Liu J, Wang Y, Song Z, Zhang Y. Nanoengineered immune check point inhibitors delivery for targeted brain cancer treatment: current status and future perspectives. Biochem Pharmacol. 2025;233:116789. https:\/\/doi.org\/10.1016\/j.bcp.2025.116789.","journal-title":"Biochem Pharmacol"},{"key":"394_CR29","doi-asserted-by":"publisher","first-page":"8231","DOI":"10.1007\/s00253-020-10802-w","volume":"104","author":"P-Y Hu","year":"2020","unstructured":"Hu P-Y, Fan X-M, Zhang Y-N, Wang S-B, Wan W-J, Pan H-Y, et al. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them. Appl Microbiol Biotechnol. 2020;104:8231\u201342. https:\/\/doi.org\/10.1007\/s00253-020-10802-w.","journal-title":"Appl Microbiol Biotechnol"},{"key":"394_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","volume":"7","author":"Y Tian","year":"2022","unstructured":"Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target Ther. 2022;7:117. https:\/\/doi.org\/10.1038\/s41392-022-00951-x.","journal-title":"Signal Transduct Target Ther"},{"key":"394_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12943-022-01712-8","volume":"22","author":"Z Huang","year":"2023","unstructured":"Huang Z, Dewanjee S, Chakraborty P, Jha NK, Dey A, Gangopadhyay M, et al. CAR T cells: engineered immune cells to treat brain cancers and beyond. Mol Cancer. 2023;22:22. https:\/\/doi.org\/10.1186\/s12943-022-01712-8.","journal-title":"Mol Cancer"},{"key":"394_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/practneurol-2020-002550","volume":"20","author":"L Neill","year":"2020","unstructured":"Neill L, Rees J, Roddie C. Neurotoxicity\u2014CAR T-cell therapy: what the neurologist needs to know. Pract Neurol. 2020;20:285\u201393. https:\/\/doi.org\/10.1136\/practneurol-2020-002550.","journal-title":"Pract Neurol"},{"key":"394_CR33","doi-asserted-by":"publisher","unstructured":"Sooreshjani M, Tripathi S, Dussold C, Najem H, de Groot J, Lukas RV, et al. The use of targeted cytokines as cancer therapeutics in glioblastoma. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/cancers15143739.","DOI":"10.3390\/cancers15143739"},{"key":"394_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/9749363","volume":"2022","author":"N Abd-Aziz","year":"2022","unstructured":"Abd-Aziz N, Poh CL. Development of peptide-based vaccines for cancer. J Oncol. 2022;2022:1\u201317. https:\/\/doi.org\/10.1155\/2022\/9749363.","journal-title":"J Oncol"},{"key":"394_CR35","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1158\/1535-7163.MCT-22-0503","volume":"22","author":"H Hosseinalizadeh","year":"2023","unstructured":"Hosseinalizadeh H, Rahmati M, Ebrahimi A, O\u2019Connor RS. Current status and challenges of vaccination therapy for glioblastoma. Mol Cancer Ther. 2023;22:435\u201346. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0503.","journal-title":"Mol Cancer Ther"},{"key":"394_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s44178-022-00021-w","volume":"1","author":"T Yang","year":"2022","unstructured":"Yang T, Shi Y, Liang T, Xing H, Ma W, Li YM, et al. Peptide vaccine against glioblastoma: from bench to bedside. Holist Integr Oncol. 2022;1:21. https:\/\/doi.org\/10.1007\/s44178-022-00021-w.","journal-title":"Holist Integr Oncol"},{"key":"394_CR37","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29:3044\u201360. https:\/\/doi.org\/10.3390\/curroncol29050247.","journal-title":"Curr Oncol"},{"key":"394_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41419-023-06389-5","volume":"15","author":"L Meng","year":"2024","unstructured":"Meng L, Wu H, Wu J, Ding P, He J, Sang M, et al. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. Cell Death Dis. 2024;15:3. https:\/\/doi.org\/10.1038\/s41419-023-06389-5.","journal-title":"Cell Death Dis"},{"key":"394_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y, Targeting. LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16:101. https:\/\/doi.org\/10.1186\/s13045-023-01499-1.","journal-title":"J Hematol Oncol"},{"key":"394_CR40","doi-asserted-by":"publisher","first-page":"100652","DOI":"10.1016\/j.oor.2024.100652","volume":"12","author":"I Desai","year":"2024","unstructured":"Desai I, Thakur S, Pagariya P. Current advances in immunotherapy for cancer. Oral Oncol Rep. 2024;12:100652. https:\/\/doi.org\/10.1016\/j.oor.2024.100652.","journal-title":"Oral Oncol Rep"},{"key":"394_CR41","doi-asserted-by":"publisher","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","volume":"143","author":"Arafat Hossain Md","year":"2024","unstructured":"Arafat Hossain Md. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol. 2024;143:113365. https:\/\/doi.org\/10.1016\/j.intimp.2024.113365.","journal-title":"Int Immunopharmacol"},{"key":"394_CR42","doi-asserted-by":"publisher","unstructured":"Hossen MM, Ma Y, Yin Z, Xia Y, Du J, Huang JY, et al. Current understanding of CTLA-4: from mechanism to autoimmune diseases. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1198365.","DOI":"10.3389\/fimmu.2023.1198365"},{"key":"394_CR43","doi-asserted-by":"publisher","unstructured":"Azarov I, Helmlinger G, Kosinsky Y, Peskov K. Elaborating on anti CTLA-4 mechanisms of action using an agent-based modeling approach. Front Appl Math Stat. 2022;8. https:\/\/doi.org\/10.3389\/fams.2022.993581.","DOI":"10.3389\/fams.2022.993581"},{"key":"394_CR44","doi-asserted-by":"publisher","unstructured":"Shibru B, Fey K, Fricke S, Blaudszun A-R, F\u00fcrst F, Weise M, et al. Detection of immune checkpoint receptors \u2013 a current challenge in clinical flow cytometry. Front Immunol. 2021;12. https:\/\/doi.org\/10.3389\/fimmu.2021.694055.","DOI":"10.3389\/fimmu.2021.694055"},{"key":"394_CR45","doi-asserted-by":"publisher","unstructured":"Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, et al. The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.964442.","DOI":"10.3389\/fimmu.2022.964442"},{"key":"394_CR46","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434\u201352. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.014.","journal-title":"Immunity"},{"key":"394_CR47","doi-asserted-by":"publisher","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 Checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8. https:\/\/doi.org\/10.3389\/fphar.2017.00561.","DOI":"10.3389\/fphar.2017.00561"},{"key":"394_CR48","doi-asserted-by":"publisher","first-page":"TPS2581","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS2581","volume":"38","author":"MS Ahluwalia","year":"2020","unstructured":"Ahluwalia MS, Peereboom DM, Ciolfi M, Schilero C, Hobbs B, Ciesielski MJ, et al. Phase II study of pembrolizumab plus SurVaxM for glioblastoma at first recurrence. J Clin Oncol. 2020;38:TPS2581\u20132581. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS2581.","journal-title":"J Clin Oncol"},{"key":"394_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.addr.2017.06.006","volume":"114","author":"JG Lyon","year":"2017","unstructured":"Lyon JG, Mokarram N, Saxena T, Carroll SL, Bellamkonda RV. Engineering challenges for brain tumor immunotherapy. Adv Drug Deliv Rev. 2017;114:19\u201332. https:\/\/doi.org\/10.1016\/j.addr.2017.06.006.","journal-title":"Adv Drug Deliv Rev"},{"key":"394_CR50","doi-asserted-by":"publisher","unstructured":"Kooti W, Esmaeili Gouvarchin Ghaleh H, Farzanehpour M, Dorostkar R, Jalali Kondori B, Bolandian M. Oncolytic viruses and cancer, do you know the main mechanism? Front Oncol 2021;11. https:\/\/doi.org\/10.3389\/fonc.2021.761015.","DOI":"10.3389\/fonc.2021.761015"},{"key":"394_CR51","doi-asserted-by":"publisher","unstructured":"Asija S, Chatterjee A, Goda JS, Yadav S, Chekuri G, Purwar R. Oncolytic immunovirotherapy for high-grade gliomas: a novel and an evolving therapeutic option. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1118246.","DOI":"10.3389\/fimmu.2023.1118246"},{"key":"394_CR52","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.annonc.2021.03.197","volume":"32","author":"AB Carpenter","year":"2021","unstructured":"Carpenter AB, Carpenter AM, Aiken R, Hanft S. Oncolytic virus in gliomas: a review of human clinical investigations. Ann Oncol. 2021;32:968\u201382. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.197.","journal-title":"Ann Oncol"},{"key":"394_CR53","doi-asserted-by":"publisher","unstructured":"Sloan AE, Buerki RA, Murphy C, Kelly AT, Ambady P, Brown M et al. LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma. Journal of Clinical Oncology. 2021;39:TPS2065\u2013TPS2065. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS2065.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS2065"},{"key":"394_CR54","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1111\/cas.13324","volume":"108","author":"J Gao","year":"2017","unstructured":"Gao J, Zheng Q, Xin N, Wang W, Zhao C. CD155, an onco-immunologic molecule in human tumors. Cancer Sci. 2017;108:1934\u20138. https:\/\/doi.org\/10.1111\/cas.13324.","journal-title":"Cancer Sci"},{"key":"394_CR55","doi-asserted-by":"publisher","first-page":"10","DOI":"10.36838\/v5i5.2","volume":"5","author":"KA Alishbha","year":"2023","unstructured":"Alishbha KA, Review Of PVSRIPO. As a Treatment for Glioblastoma. Int J High School Res. 2023;5:10\u20133. https:\/\/doi.org\/10.36838\/v5i5.2.","journal-title":"Int J High School Res"},{"key":"394_CR56","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","volume":"379","author":"A Desjardins","year":"2018","unstructured":"Desjardins A, Gromeier M, Herndon JE, Beaubier N, Bolognesi DP, Friedman AH, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379:150\u201361. https:\/\/doi.org\/10.1056\/NEJMoa1716435.","journal-title":"N Engl J Med"},{"key":"394_CR57","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/13543784.2019.1694000","volume":"28","author":"B Philbrick","year":"2019","unstructured":"Philbrick B, Adamson DC. DNX-2401: an investigational drug for the treatment of recurrent glioblastoma. Expert Opin Investig Drugs. 2019;28:1041\u20139. https:\/\/doi.org\/10.1080\/13543784.2019.1694000.","journal-title":"Expert Opin Investig Drugs"},{"key":"394_CR58","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","volume":"36","author":"FF Lang","year":"2018","unstructured":"Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36:1419\u201327. https:\/\/doi.org\/10.1200\/JCO.2017.75.8219.","journal-title":"J Clin Oncol"},{"key":"394_CR59","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/imr.12773","volume":"290","author":"D Akhavan","year":"2019","unstructured":"Akhavan D, Alizadeh D, Wang D, Weist MR, Shepphird JK, Brown CE. CAR T cells for brain tumors: lessons learned and road ahead. Immunol Rev. 2019;290:60\u201384. https:\/\/doi.org\/10.1111\/imr.12773.","journal-title":"Immunol Rev"},{"key":"394_CR60","doi-asserted-by":"publisher","unstructured":"Koppers MJA, Monnikhof M, Meeldijk J, Koorman T, Bovenschen N. Chimeric antigen receptor-macrophages: Emerging next-generation cell therapy for brain cancer. Neurooncol Adv. 2025;7. https:\/\/doi.org\/10.1093\/noajnl\/vdaf059.","DOI":"10.1093\/noajnl\/vdaf059"},{"key":"394_CR61","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","volume":"7","author":"BD Choi","year":"2019","unstructured":"Choi BD, Yu X, Castano AP, Darr H, Henderson DB, Bouffard AA, et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer. 2019;7:304. https:\/\/doi.org\/10.1186\/s40425-019-0806-7.","journal-title":"J Immunother Cancer"},{"key":"394_CR62","doi-asserted-by":"publisher","unstructured":"Jin L, Ge H, Long Y, Yang C, Chang Y (Emily), Mu L CD70, et al. editors. a novel target of CAR T-cell therapy for gliomas. Neuro Oncol 2018;20:55\u201365. https:\/\/doi.org\/10.1093\/neuonc\/nox116","DOI":"10.1093\/neuonc\/nox116"},{"key":"394_CR63","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25:2560\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0432.","journal-title":"Clin Cancer Res"},{"key":"394_CR64","doi-asserted-by":"publisher","unstructured":"Yang L, Ning Q, Tang SS. Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment. J Immunol Res 2022;2022. https:\/\/doi.org\/10.1155\/2022\/8052212","DOI":"10.1155\/2022\/8052212"},{"key":"394_CR65","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejca.2021.10.027","volume":"160","author":"C Corti","year":"2022","unstructured":"Corti C, Giachetti PPMB, Eggermont AMM, Delaloge S, Curigliano G. Therapeutic vaccines for breast cancer: has the time finally come? Eur J Cancer. 2022;160:150\u201374. https:\/\/doi.org\/10.1016\/j.ejca.2021.10.027.","journal-title":"Eur J Cancer"},{"key":"394_CR66","doi-asserted-by":"publisher","first-page":"104963","DOI":"10.1016\/j.ebiom.2023.104963","volume":"100","author":"Z Xiong","year":"2024","unstructured":"Xiong Z, Raphael I, Olin M, Okada H, Li X, Kohanbash G. Glioblastoma vaccines: past, present, and opportunities. EBioMedicine. 2024;100:104963. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104963.","journal-title":"EBioMedicine"},{"key":"394_CR67","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1158\/2159-8290.CD-18-1357","volume":"9","author":"PA Ott","year":"2019","unstructured":"Ott PA, Wu CJ. Cancer vaccines: Steering t cells down the right path to eradicate tumors. Cancer Discov. 2019;9:476\u201381. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1357.","journal-title":"Cancer Discov"},{"key":"394_CR68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12672-022-00491-4","volume":"13","author":"E Grimmett","year":"2022","unstructured":"Grimmett E, Al-Share B, Alkassab MB, Zhou RW, Desai A, Rahim MMA, et al. Cancer vaccines: past, present and future; a review article. Discover Oncol. 2022;13:31. https:\/\/doi.org\/10.1007\/s12672-022-00491-4.","journal-title":"Discover Oncol"},{"key":"394_CR69","doi-asserted-by":"publisher","unstructured":"Singh P, Khatib MN, Kaur RR, Srivastava M, Barwal M. A, Advancements and challenges in personalized neoantigen-based cancer vaccines. Oncol Rev. 2025;19. https:\/\/doi.org\/10.3389\/or.2025.1541326.","DOI":"10.3389\/or.2025.1541326"},{"key":"394_CR70","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-025-01670-w","volume":"18","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Wei Y, Tian X, Wei X. Cancer vaccines: current status and future directions. J Hematol Oncol. 2025;18:18. https:\/\/doi.org\/10.1186\/s13045-025-01670-w.","journal-title":"J Hematol Oncol"},{"key":"394_CR71","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/vaccines6030052","volume":"6","author":"A Terbuch","year":"2018","unstructured":"Terbuch A, Lopez J. Next generation cancer vaccines\u2014make it personal! Vaccines. (Basel). 2018;6:52. https:\/\/doi.org\/10.3390\/vaccines6030052.","journal-title":"(Basel)"},{"key":"394_CR72","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13041-025-01221-x","volume":"18","author":"R Salahlou","year":"2025","unstructured":"Salahlou R, Farajnia S, Alizadeh E, Dastmalchi S. Recent developments in peptide vaccines against glioblastoma, a review and update. Mol Brain. 2025;18:50. https:\/\/doi.org\/10.1186\/s13041-025-01221-x.","journal-title":"Mol Brain"},{"key":"394_CR73","doi-asserted-by":"publisher","unstructured":"Nan J, Yang W, Xie Y, Yu M, Chen Y, Zhang J. Emerging nano-immunotherapeutic approaches to glioma. Small Struct. 2023;4. https:\/\/doi.org\/10.1002\/sstr.202300016.","DOI":"10.1002\/sstr.202300016"},{"key":"394_CR74","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s41016-022-00301-4","volume":"8","author":"Z Wang","year":"2022","unstructured":"Wang Z, Huang R, Han B, Wu F, Sun Z, Li G, et al. Identification of tumor-associated antigens and immune subtypes of lower-grade glioma and glioblastoma for mRNA vaccine development. Chin Neurosurg J. 2022;8:34. https:\/\/doi.org\/10.1186\/s41016-022-00301-4.","journal-title":"Chin Neurosurg J"},{"key":"394_CR75","doi-asserted-by":"publisher","unstructured":"Solinas C, Aiello M, Migliori E, Willard-Gallo K, Emens LA. Breast cancer vaccines: Heeding the lessons of the past to guide a path forward. Cancer Treat Rev. 2020;84. https:\/\/doi.org\/10.1016\/j.ctrv.2019.101947.","DOI":"10.1016\/j.ctrv.2019.101947"},{"key":"394_CR76","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1172\/JCI140378","volume":"130","author":"S Mueller","year":"2020","unstructured":"Mueller S, Taitt JM, Villanueva-Meyer JE, Bonner ER, Nejo T, Lulla RR, et al. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. J Clin Invest. 2020;130:6325\u201337. https:\/\/doi.org\/10.1172\/JCI140378.","journal-title":"J Clin Invest"},{"key":"394_CR77","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/1078-0432.CCR-21-2867","volume":"28","author":"JL Hu","year":"2022","unstructured":"Hu JL, Omofoye OA, Rudnick JD, Kim S, Tighiouart M, Phuphanich S, et al. A phase I study of autologous dendritic cell vaccine pulsed with allogeneic stem-like cell line lysate in patients with newly diagnosed or recurrent glioblastoma. Clin Cancer Res. 2022;28:689\u201396. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2867.","journal-title":"Clin Cancer Res"},{"key":"394_CR78","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1038\/s41467-024-48073-y","volume":"15","author":"RG Everson","year":"2024","unstructured":"Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, et al. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nat Commun. 2024;15:3882. https:\/\/doi.org\/10.1038\/s41467-024-48073-y.","journal-title":"Nat Commun"},{"key":"394_CR79","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","volume":"9","author":"LM Liau","year":"2023","unstructured":"Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma. JAMA Oncol. 2023;9:112. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5370.","journal-title":"JAMA Oncol"},{"key":"394_CR80","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","volume":"592","author":"M Platten","year":"2021","unstructured":"Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature. 2021;592:463\u20138. https:\/\/doi.org\/10.1038\/s41586-021-03363-z.","journal-title":"Nature"},{"key":"394_CR81","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1200\/JCO.2023.41.16_suppl.2052","volume":"41","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Ji N, Chen G, Wu H, Wang Y, Li X, et al. H3.3-K27M neoantigen vaccine elicits anti-tumor T cell immunity against diffuse intrinsic pontine glioma: The phase I ENACTING trial. J Clin Oncol. 2023;41:2052\u20132052. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.2052.","journal-title":"J Clin Oncol"},{"key":"394_CR82","doi-asserted-by":"publisher","first-page":"101324","DOI":"10.1016\/j.mam.2024.101324","volume":"101","author":"F Ruzzi","year":"2025","unstructured":"Ruzzi F, Riccardo F, Conti L, Tarone L, Semprini MS, Bolli E, et al. Cancer vaccines: target antigens, vaccine platforms and preclinical models. Mol Aspects Med. 2025;101:101324. https:\/\/doi.org\/10.1016\/j.mam.2024.101324.","journal-title":"Mol Aspects Med"},{"key":"394_CR83","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12929-024-01102-w","volume":"32","author":"H-C Liao","year":"2025","unstructured":"Liao H-C, Liu S-J. Advances in nucleic acid-based cancer vaccines. J Biomed Sci. 2025;32:10. https:\/\/doi.org\/10.1186\/s12929-024-01102-w.","journal-title":"J Biomed Sci"},{"key":"394_CR84","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s12032-023-02060-3","volume":"40","author":"A Pandya","year":"2023","unstructured":"Pandya A, Shah Y, Kothari N, Postwala H, Shah A, Parekh P, et al. The future of cancer immunotherapy: DNA vaccines leading the way. Med Oncol. 2023;40:200. https:\/\/doi.org\/10.1007\/s12032-023-02060-3.","journal-title":"Med Oncol"},{"key":"394_CR85","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","volume":"23","author":"C Liu","year":"2023","unstructured":"Liu C, Shi Q, Huang X, Koo S, Kong N, Tao W. mRNA-based cancer therapeutics. Nat Rev Cancer. 2023;23:526\u201343. https:\/\/doi.org\/10.1038\/s41568-023-00586-2.","journal-title":"Nat Rev Cancer"},{"key":"394_CR86","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3390\/vaccines12080950","volume":"12","author":"D Liu","year":"2024","unstructured":"Liu D, Liu L, Li X, Wang S, Wu G, Che X. Advancements and challenges in peptide-based cancer vaccination: a multidisciplinary perspective. Vaccines (Basel). 2024;12:950. https:\/\/doi.org\/10.3390\/vaccines12080950.","journal-title":"Vaccines (Basel)"},{"key":"394_CR87","doi-asserted-by":"publisher","unstructured":"Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW et al. Therapeutic cancer vaccines. Adv. Cancer Res. Academic Press Inc. 2014;121:67\u2013124. https:\/\/doi.org\/10.1016\/B978-0-12-800249-0.00002-0.","DOI":"10.1016\/B978-0-12-800249-0.00002-0"},{"key":"394_CR88","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.3390\/cancers15123251","volume":"15","author":"L Gatto","year":"2023","unstructured":"Gatto L, Di Nunno V, Tosoni A, Bartolini S, Ranieri L, Franceschi E. DCVax-L Vaccination in patients with glioblastoma: real promise or negative trial? Debate Is Open Cancers (Basel). 2023;15:3251. https:\/\/doi.org\/10.3390\/cancers15123251.","journal-title":"Debate Is Open Cancers (Basel)"},{"key":"394_CR89","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.1158\/1078-0432.CCR-20-1082","volume":"26","author":"KA Batich","year":"2020","unstructured":"Batich KA, Mitchell DA, Healy P, Herndon JE, Sampson JH. Once, twice, three times a finding: reproducibility of dendritic cell vaccine trials targeting cytomegalovirus in glioblastoma. Clin Cancer Res. 2020;26:5297\u2013303. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1082.","journal-title":"Clin Cancer Res"},{"key":"394_CR90","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3390\/vaccines3020344","volume":"3","author":"C Chiang","year":"2015","unstructured":"Chiang C, Coukos G, Kandalaft L. Whole tumor antigen vaccines: where are we? Vaccines (Basel). 2015;3:344\u201372. https:\/\/doi.org\/10.3390\/vaccines3020344.","journal-title":"Vaccines (Basel)"},{"key":"394_CR91","doi-asserted-by":"publisher","unstructured":"Abousalman-Rezvani Z, Refaat A, Dehghankelishadi P, Roghani\u2010Mamaqani H, Esser L, Voelcker NH. Insights into targeted and stimulus\u2010responsive nanocarriers for brain cancer treatment. Adv Healthc Mater. 2024;13. https:\/\/doi.org\/10.1002\/adhm.202302902.","DOI":"10.1002\/adhm.202302902"},{"key":"394_CR92","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.ctrv.2013.05.007","volume":"39","author":"A Bregy","year":"2013","unstructured":"Bregy A, Wong TM, Shah AH, Goldberg JM, Komotar RJ. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. Cancer Treat Rev. 2013;39:891\u2013907. https:\/\/doi.org\/10.1016\/j.ctrv.2013.05.007.","journal-title":"Cancer Treat Rev"},{"key":"394_CR93","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis CD, Ferraro GB, Jain RK. The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20:26\u201341. https:\/\/doi.org\/10.1038\/s41568-019-0205-x.","journal-title":"Nat Rev Cancer"},{"key":"394_CR94","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s12032-023-02220-5","volume":"40","author":"ME Pour","year":"2023","unstructured":"Pour ME, Moghadam SG, Shirkhani P, Sahebkar A, Mosaffa F. Therapeutic cell-based vaccines for glioblastoma multiforme. Med Oncol. 2023;40:354. https:\/\/doi.org\/10.1007\/s12032-023-02220-5.","journal-title":"Med Oncol"},{"key":"394_CR95","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3390\/pharmaceutics12121205","volume":"12","author":"JI Griffith","year":"2020","unstructured":"Griffith JI, Rathi S, Zhang W, Zhang W, Drewes LR, Sarkaria JN, et al. Addressing BBB heterogeneity: a new paradigm for drug delivery to brain tumors. Pharmaceutics. 2020;12:1205. https:\/\/doi.org\/10.3390\/pharmaceutics12121205.","journal-title":"Pharmaceutics"},{"key":"394_CR96","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.2174\/138920112803341798","volume":"13","author":"C Zhan","year":"2012","unstructured":"Zhan C, Lu W. The blood-brain\/tumor barriers: challenges and chances for malignant gliomas targeted drug delivery. Curr Pharm Biotechnol. 2012;13:2380\u20137. https:\/\/doi.org\/10.2174\/138920112803341798.","journal-title":"Curr Pharm Biotechnol"},{"key":"394_CR97","doi-asserted-by":"publisher","first-page":"12654","DOI":"10.3390\/ijms222312654","volume":"22","author":"F Mo","year":"2021","unstructured":"Mo F, Pellerino A, Soffietti R, Rud\u00e0 R. Blood\u2013brain barrier in brain tumors: biology and clinical relevance. Int J Mol Sci. 2021;22:12654. https:\/\/doi.org\/10.3390\/ijms222312654.","journal-title":"Int J Mol Sci"},{"key":"394_CR98","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3390\/cancers13040761","volume":"13","author":"A Becker","year":"2021","unstructured":"Becker A, Sells B, Haque S, Chakravarti A. Tumor heterogeneity in glioblastomas: from light microscopy to molecular pathology. Cancers (Basel). 2021;13:761. https:\/\/doi.org\/10.3390\/cancers13040761.","journal-title":"Cancers (Basel)"},{"key":"394_CR99","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41698-024-00753-0","volume":"8","author":"S Park","year":"2024","unstructured":"Park S, Maus MV, Choi BD. CAR-T cell therapy for the treatment of adult high-grade gliomas. NPJ Precis Oncol. 2024;8:279. https:\/\/doi.org\/10.1038\/s41698-024-00753-0.","journal-title":"NPJ Precis Oncol"},{"key":"394_CR100","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ijms20061283","volume":"20","author":"M-R Benmebarek","year":"2019","unstructured":"Benmebarek M-R, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of Chimeric Antigen Receptor (CAR) T cells. Int J Mol Sci. 2019;20:1283. https:\/\/doi.org\/10.3390\/ijms20061283.","journal-title":"Int J Mol Sci"},{"key":"394_CR101","doi-asserted-by":"publisher","first-page":"14256","DOI":"10.3390\/ijms241814256","volume":"24","author":"N Rabah","year":"2023","unstructured":"Rabah N, Ait Mohand F-E, Kravchenko-Balasha N. Understanding glioblastoma signaling, heterogeneity, invasiveness, and drug delivery barriers. Int J Mol Sci. 2023;24:14256. https:\/\/doi.org\/10.3390\/ijms241814256.","journal-title":"Int J Mol Sci"},{"key":"394_CR102","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/cancers17050817","volume":"17","author":"N Vallieri","year":"2025","unstructured":"Vallieri N, Datsi A. Immune cell interplay in the fight against GBM. Cancers (Basel). 2025;17:817. https:\/\/doi.org\/10.3390\/cancers17050817.","journal-title":"Cancers (Basel)"},{"key":"394_CR103","doi-asserted-by":"publisher","first-page":"e1149674","DOI":"10.1080\/2162402X.2016.1149674","volume":"5","author":"A Buqu\u00e9","year":"2016","unstructured":"Buqu\u00e9 A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman WH, et al. Trial Watch\u2014Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology. 2016;5:e1149674. https:\/\/doi.org\/10.1080\/2162402X.2016.1149674.","journal-title":"Oncoimmunology"},{"key":"394_CR104","doi-asserted-by":"publisher","first-page":"17556","DOI":"10.1038\/s41598-017-17752-w","volume":"7","author":"A Gieryng","year":"2017","unstructured":"Gieryng A, Pszczolkowska D, Bocian K, Dabrowski M, Rajan WD, Kloss M, et al. Immune microenvironment of experimental rat C6 gliomas resembles human glioblastomas. Sci Rep. 2017;7:17556. https:\/\/doi.org\/10.1038\/s41598-017-17752-w.","journal-title":"Sci Rep"},{"key":"394_CR105","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3109\/08820139.2012.689591","volume":"41","author":"G Kohanbash","year":"2012","unstructured":"Kohanbash G, Okada H. Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development. Immunol Invest. 2012;41:658\u201379. https:\/\/doi.org\/10.3109\/08820139.2012.689591.","journal-title":"Immunol Invest"},{"key":"394_CR106","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","volume":"19","author":"C Li","year":"2020","unstructured":"Li C, Jiang P, Wei S, Xu X, Wang J. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer. 2020;19:116. https:\/\/doi.org\/10.1186\/s12943-020-01234-1.","journal-title":"Mol Cancer"},{"key":"394_CR107","doi-asserted-by":"publisher","first-page":"112922","DOI":"10.1016\/j.intimp.2024.112922","volume":"141","author":"B Yin","year":"2024","unstructured":"Yin B, Cai Y, Chen L, Li Z, Li X. Immunosuppressive MDSC and Treg signatures predict prognosis and therapeutic response in glioma. Int Immunopharmacol. 2024;141:112922. https:\/\/doi.org\/10.1016\/j.intimp.2024.112922.","journal-title":"Int Immunopharmacol"},{"key":"394_CR108","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","volume":"6","author":"X Xiang","year":"2021","unstructured":"Xiang X, Wang J, Lu D, Xu X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Ther. 2021;6:75. https:\/\/doi.org\/10.1038\/s41392-021-00484-9.","journal-title":"Signal Transduct Target Ther"},{"key":"394_CR109","doi-asserted-by":"publisher","unstructured":"Onohuean H, Ogunmola T, Adesiyan A, Oluwamayowa Samuel A, Oni E, Okechukwu Paul Chima U. Updates on cancer vaccines in brain cancer: Advances in neuroblastoma, delivery systems, and emerging technologies. Hum Vaccin Immunother. 2025;21. https:\/\/doi.org\/10.1080\/21645515.2025.2526964.","DOI":"10.1080\/21645515.2025.2526964"},{"key":"394_CR110","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood\u2013brain barrier: structure, regulation and drug delivery. Signal Transduct Target Ther. 2023;8:217. https:\/\/doi.org\/10.1038\/s41392-023-01481-w.","journal-title":"Signal Transduct Target Ther"},{"key":"394_CR111","doi-asserted-by":"publisher","first-page":"120351","DOI":"10.1016\/j.ijpharm.2021.120351","volume":"599","author":"M Choudhari","year":"2021","unstructured":"Choudhari M, Hejmady S, Narayan Saha R, Damle S, Singhvi G, Alexander A, et al. Evolving new-age strategies to transport therapeutics across the blood-brain-barrier. Int J Pharm. 2021;599:120351. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120351.","journal-title":"Int J Pharm"},{"key":"394_CR112","doi-asserted-by":"publisher","first-page":"7449","DOI":"10.3390\/jcm13237449","volume":"13","author":"P Pourmasoumi","year":"2024","unstructured":"Pourmasoumi P, Banihashemian SA, Zamani F, Rasouli-Nia A, Mehrabani D, Karimi-Busheri F. Nanoparticle-based approaches in the diagnosis and treatment of brain tumors. J Clin Med. 2024;13:7449. https:\/\/doi.org\/10.3390\/jcm13237449.","journal-title":"J Clin Med"},{"key":"394_CR113","doi-asserted-by":"publisher","unstructured":"McLoughlin CD, Nevins S, Stein JB, Khakbiz M, Lee K. Overcoming the blood\u2013brain barrier: multifunctional nanomaterial-based strategies for targeted drug delivery in neurological disorders. Small Sci. 2024;4. https:\/\/doi.org\/10.1002\/smsc.202400232.","DOI":"10.1002\/smsc.202400232"},{"key":"394_CR114","doi-asserted-by":"publisher","unstructured":"Lim SH, Yee GT, Khang D. Nanoparticle-based combinational strategies for overcoming the blood-brain barrier and blood-tumor barrier. Int J Nanomed 2024;Volume 19:2529\u201352. https:\/\/doi.org\/10.2147\/IJN.S450853.","DOI":"10.2147\/IJN.S450853"},{"key":"394_CR115","doi-asserted-by":"publisher","unstructured":"Yaghi NK, Wei J, Hashimoto Y, Kong L-Y, Gabrusiewicz K, Nduom EK, et al. Immune modulatory nanoparticle therapeutics for intracerebral glioma. Neuro Oncol. 2016;198. https:\/\/doi.org\/10.1093\/neuonc\/now198.","DOI":"10.1093\/neuonc\/now198"},{"key":"394_CR116","doi-asserted-by":"publisher","first-page":"e1256527","DOI":"10.1080\/2162402X.2016.1256527","volume":"6","author":"EJ Sayour","year":"2017","unstructured":"Sayour EJ, De Leon G, Pham C, Grippin A, Kemeny H, Chua J, et al. Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles. Oncoimmunology. 2017;6:e1256527. https:\/\/doi.org\/10.1080\/2162402X.2016.1256527.","journal-title":"Oncoimmunology"},{"key":"394_CR117","doi-asserted-by":"publisher","first-page":"vi258","DOI":"10.1093\/neuonc\/noy148.1071","volume":"20","author":"A Grippin","year":"2018","unstructured":"Grippin A, Mendez-Gomez H, Wummer B, Wildes T, Dyson K, Valladares D, et al. TMIC-12. Tumor-homing RNA-nanoparticles reprogram immune cells in the brain tumor microenvironment. Neuro Oncol. 2018;20:vi258\u2013258. https:\/\/doi.org\/10.1093\/neuonc\/noy148.1071.","journal-title":"Neuro Oncol"},{"key":"394_CR118","doi-asserted-by":"publisher","first-page":"133848","DOI":"10.1016\/j.cej.2021.133848","volume":"433","author":"Y Yin","year":"2022","unstructured":"Yin Y, Tang W, Ma X, Tang L, Zhang Y, Yang M, et al. Biomimetic neutrophil and macrophage dual membrane-coated nanoplatform with orchestrated tumor-microenvironment responsive capability promotes therapeutic efficacy against glioma. Chem Eng J. 2022;433:133848. https:\/\/doi.org\/10.1016\/j.cej.2021.133848.","journal-title":"Chem Eng J"},{"key":"394_CR119","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1007\/s13346-023-01509-2","volume":"14","author":"F Sousa","year":"2024","unstructured":"Sousa F, Lee H, Almeida M, Bazzoni A, Rothen-Rutishauser B, Petri-Fink A. Immunostimulatory nanoparticles delivering cytokines as a novel cancer nanoadjuvant to empower glioblastoma immunotherapy. Drug Deliv Transl Res. 2024;14:2655\u201367. https:\/\/doi.org\/10.1007\/s13346-023-01509-2.","journal-title":"Drug Deliv Transl Res"},{"key":"394_CR120","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1021\/acs.nanolett.9b05171","volume":"20","author":"J Ma","year":"2020","unstructured":"Ma J, Liu F, Sheu WC, Meng Z, Xie Y, Xu H, et al. Copresentation of tumor antigens and costimulatory molecules via biomimetic nanoparticles for effective cancer immunotherapy. Nano Lett. 2020;20:4084\u201394. https:\/\/doi.org\/10.1021\/acs.nanolett.9b05171.","journal-title":"Nano Lett"},{"key":"394_CR121","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1021\/acsnano.2c09033","volume":"17","author":"X Ma","year":"2023","unstructured":"Ma X, Kuang L, Yin Y, Tang L, Zhang Y, Fan Q, et al. Tumor\u2013antigen activated dendritic cell membrane-coated biomimetic nanoparticles with orchestrating immune responses promote therapeutic efficacy against glioma. ACS Nano. 2023;17:2341\u201355. https:\/\/doi.org\/10.1021\/acsnano.2c09033.","journal-title":"ACS Nano"},{"key":"394_CR122","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.bioactmat.2020.04.011","volume":"5","author":"GB Kim","year":"2020","unstructured":"Kim GB, Aragon-Sanabria V, Randolph L, Jiang H, Reynolds JA, Webb BS, et al. High-affinity mutant Interleukin-13 targeted CAR T cells enhance delivery of clickable biodegradable fluorescent nanoparticles to glioblastoma. Bioact Mater. 2020;5:624\u201335. https:\/\/doi.org\/10.1016\/j.bioactmat.2020.04.011.","journal-title":"Bioact Mater"},{"key":"394_CR123","doi-asserted-by":"publisher","first-page":"122904","DOI":"10.1016\/j.biomaterials.2024.122904","volume":"315","author":"J Lee","year":"2025","unstructured":"Lee J, Kang Y, Lee H, Saravanakumar G, Park SA, Ahn S, et al. Amplifying glioblastoma immunotherapy: T cell shielding through nitric oxide\/reactive oxygen species scavenging nanoparticles Potentiates anti-PD-1. Biomaterials. 2025;315:122904. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122904.","journal-title":"Biomaterials"},{"key":"394_CR124","doi-asserted-by":"publisher","first-page":"7961","DOI":"10.1007\/s13277-015-3486-z","volume":"36","author":"M Li","year":"2015","unstructured":"Li M, Wang B, Wu Z, Shi X, Zhang J, Han S. Treatment of Dutch rat models of glioma using EphrinA1-PE38\/GM-CSF chitosan nanoparticles by in situ activation of dendritic cells. Tumor Biology. 2015;36:7961\u20136. https:\/\/doi.org\/10.1007\/s13277-015-3486-z.","journal-title":"Tumor Biology"},{"key":"394_CR125","doi-asserted-by":"publisher","first-page":"17309","DOI":"10.1021\/acsnano.4c14573","volume":"19","author":"Y Zou","year":"2025","unstructured":"Zou Y, Li S, Li Y, Zhang D, Zheng M, Shi B. Glioblastoma cell derived exosomes as a potent vaccine platform targeting primary brain cancers and brain metastases. ACS Nano. 2025;19:17309\u201322. https:\/\/doi.org\/10.1021\/acsnano.4c14573.","journal-title":"ACS Nano"},{"key":"394_CR126","doi-asserted-by":"publisher","unstructured":"Liaw K, Reddy R, Sharma A, Li J, Chang M, Sharma R, et al. Targeted systemic dendrimer delivery of <\u2009scp>CSF-1R inhibitor to tumor\u2010associated macrophages improves outcomes in orthotopic glioblastoma. Bioeng Transl Med. 2021;6. https:\/\/doi.org\/10.1002\/btm2.10205.","DOI":"10.1002\/btm2.10205"},{"key":"394_CR127","doi-asserted-by":"publisher","first-page":"7677","DOI":"10.2147\/IJN.S440405","volume":"18","author":"S-F Chen","year":"2023","unstructured":"Chen S-F, Kau M, Wang Y-C, Chen M-H, Tung F-I, Chen M-H, et al. Synergistically enhancing immunotherapy efficacy in glioblastoma with gold-core silica-shell nanoparticles and radiation. Int J Nanomed. 2023;18:7677\u201393. https:\/\/doi.org\/10.2147\/IJN.S440405.","journal-title":"Int J Nanomed"},{"key":"394_CR128","doi-asserted-by":"publisher","first-page":"8318","DOI":"10.1021\/acs.nanolett.9b03968","volume":"19","author":"S Ruan","year":"2019","unstructured":"Ruan S, Xie R, Qin L, Yu M, Xiao W, Hu C, et al. Aggregable nanoparticles-enabled chemotherapy and autophagy inhibition combined with anti-PD-L1 antibody for improved glioma treatment. Nano Lett. 2019;19:8318\u201332. https:\/\/doi.org\/10.1021\/acs.nanolett.9b03968.","journal-title":"Nano Lett"},{"key":"394_CR129","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jconrel.2015.10.051","volume":"220","author":"MA Shevtsov","year":"2015","unstructured":"Shevtsov MA, Nikolaev BP, Yakovleva LY, Parr MA, Marchenko YY, Eliseev I, et al. 70-kDa heat shock protein coated magnetic nanocarriers as a nanovaccine for induction of anti-tumor immune response in experimental glioma. J Controlled Release. 2015;220:329\u201340. https:\/\/doi.org\/10.1016\/j.jconrel.2015.10.051.","journal-title":"J Controlled Release"},{"key":"394_CR130","doi-asserted-by":"publisher","first-page":"101463","DOI":"10.1016\/j.omtm.2025.101463","volume":"33","author":"S Xu","year":"2025","unstructured":"Xu S, Hu Z, Song F, Xu Y, Han X. Lipid nanoparticles: composition, formulation, and application. Mol Ther Methods Clin Dev. 2025;33:101463. https:\/\/doi.org\/10.1016\/j.omtm.2025.101463.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"394_CR131","doi-asserted-by":"publisher","first-page":"100305","DOI":"10.1016\/j.ijpx.2024.100305","volume":"8","author":"AS Alfutaimani","year":"2024","unstructured":"Alfutaimani AS, Alharbi NK, Alahmari S, Alqabbani AA, Aldayel A. Exploring the landscape of Lipid Nanoparticles (LNPs): a comprehensive review of LNPs types and biological sources of lipids. Int J Pharm X. 2024;8:100305. https:\/\/doi.org\/10.1016\/j.ijpx.2024.100305.","journal-title":"Int J Pharm X"},{"key":"394_CR132","doi-asserted-by":"publisher","first-page":"e09575","DOI":"10.1016\/j.heliyon.2022.e09575","volume":"8","author":"SRK Pandian","year":"2022","unstructured":"Pandian SRK, Vijayakumar KK, Murugesan S, Kunjiappan S, Liposomes. An emerging carrier for targeting Alzheimer\u2019s and Parkinson\u2019s diseases. Heliyon. 2022;8:e09575. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09575.","journal-title":"Heliyon"},{"key":"394_CR133","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.3390\/ijms24032643","volume":"24","author":"S Wang","year":"2023","unstructured":"Wang S, Chen Y, Guo J, Huang Q. Liposomes for tumor targeted therapy: a review. Int J Mol Sci. 2023;24:2643. https:\/\/doi.org\/10.3390\/ijms24032643.","journal-title":"Int J Mol Sci"},{"key":"394_CR134","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/pharmaceutics12030264","volume":"12","author":"M-K Lee","year":"2020","unstructured":"Lee M-K. Liposomes for enhanced bioavailability of water-insoluble drugs: in vivo evidence and recent approaches. Pharmaceutics. 2020;12:264. https:\/\/doi.org\/10.3390\/pharmaceutics12030264.","journal-title":"Pharmaceutics"},{"key":"394_CR135","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1111\/ajt.16591","volume":"21","author":"A Prunevieille","year":"2021","unstructured":"Prunevieille A, Babiker-Mohamed MH, Aslami C, Gonzalez-Nolasco B, Mooney N, Benichou G. T cell antigenicity and immunogenicity of allogeneic exosomes. Am J Transplant. 2021;21:2583\u20139. https:\/\/doi.org\/10.1111\/ajt.16591.","journal-title":"Am J Transplant"},{"key":"394_CR136","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.2147\/IJN.S444582","volume":"18","author":"J Tian","year":"2023","unstructured":"Tian J, Han Z, Song D, Peng Y, Xiong M, Chen Z, et al. Engineered exosome for drug delivery: recent development and clinical applications. Int J Nanomed. 2023;18:7923\u201340. https:\/\/doi.org\/10.2147\/IJN.S444582.","journal-title":"Int J Nanomed"},{"key":"394_CR137","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12951-025-03528-2","volume":"23","author":"N Sanadgol","year":"2025","unstructured":"Sanadgol N, Abedi M, Hashemzaei M, Kamran Z, Khalseh R, Beyer C, et al. Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges. J Nanobiotechnol. 2025;23:453. https:\/\/doi.org\/10.1186\/s12951-025-03528-2.","journal-title":"J Nanobiotechnol"},{"key":"394_CR138","doi-asserted-by":"publisher","first-page":"117296","DOI":"10.1016\/j.biopha.2024.117296","volume":"179","author":"J Ye","year":"2024","unstructured":"Ye J, Li D, Jie Y, Luo H, Zhang W, Qiu C. Exosome-based nanoparticles and cancer immunotherapy. Biomed Pharmacother. 2024;179:117296. https:\/\/doi.org\/10.1016\/j.biopha.2024.117296.","journal-title":"Biomed Pharmacother"},{"key":"394_CR139","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jconrel.2022.03.036","volume":"345","author":"FU Rehman","year":"2022","unstructured":"Rehman FU, Liu Y, Yang Q, Yang H, Liu R, Zhang D, et al. Heme Oxygenase-1 targeting exosomes for temozolomide resistant glioblastoma synergistic therapy. J Controlled Release. 2022;345:696\u2013708. https:\/\/doi.org\/10.1016\/j.jconrel.2022.03.036.","journal-title":"J Controlled Release"},{"key":"394_CR140","doi-asserted-by":"publisher","unstructured":"Wu T, Liu Y, Cao Y, Liu Z. Engineering macrophage exosome disguised biodegradable nanoplatform for enhanced sonodynamic therapy of glioblastoma. Adv Mater. 2022;34. https:\/\/doi.org\/10.1002\/adma.202110364.","DOI":"10.1002\/adma.202110364"},{"key":"394_CR141","doi-asserted-by":"publisher","unstructured":"Bao P, Gu H, Ye J, He J, Zhong Z, Yu A, et al. Chimeric exosomes functionalized with STING activation for personalized glioblastoma immunotherapy. Adv Sci. 2024;11. https:\/\/doi.org\/10.1002\/advs.202306336.","DOI":"10.1002\/advs.202306336"},{"key":"394_CR142","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1186\/s12967-025-06814-7","volume":"23","author":"A Javdani-Mallak","year":"2025","unstructured":"Javdani-Mallak A, Mowla SJ, Alibolandi M. Tumor-derived exosomes and their application in cancer treatment. J Transl Med. 2025;23:751. https:\/\/doi.org\/10.1186\/s12967-025-06814-7.","journal-title":"J Transl Med"},{"key":"394_CR143","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12964-020-00700-z","volume":"19","author":"S Shen","year":"2021","unstructured":"Shen S, Song Y, Zhao B, Xu Y, Ren X, Zhou Y, et al. Cancer-derived exosomal miR-7641 promotes breast cancer progression and metastasis. Cell Communication Signal. 2021;19:20. https:\/\/doi.org\/10.1186\/s12964-020-00700-z.","journal-title":"Cell Communication Signal"},{"key":"394_CR144","doi-asserted-by":"publisher","first-page":"102748","DOI":"10.1016\/j.nantod.2025.102748","volume":"63","author":"S Li","year":"2025","unstructured":"Li S, Zhang D, Wang Y, Ismail M, He W, Zheng M, et al. Tumor cell-derived engineered exosome enhances effective immunotherapy for orthotopic glioblastoma and its recurrences. Nano Today. 2025;63:102748. https:\/\/doi.org\/10.1016\/j.nantod.2025.102748.","journal-title":"Nano Today"},{"key":"394_CR145","doi-asserted-by":"publisher","first-page":"213118","DOI":"10.1016\/j.bioadv.2022.213118","volume":"141","author":"H Choudhury","year":"2022","unstructured":"Choudhury H, Pandey M, Mohgan R, Jong JSJ, David RN, Ngan WY, et al. Dendrimer-based delivery of macromolecules for the treatment of brain tumor. Biomaterials Adv. 2022;141:213118. https:\/\/doi.org\/10.1016\/j.bioadv.2022.213118.","journal-title":"Biomaterials Adv"},{"key":"394_CR146","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3390\/molecules25030490","volume":"25","author":"N \u0160amec","year":"2020","unstructured":"\u0160amec N, Zottel A, Videti\u010d Paska A, Jov\u010devska I. Nanomedicine and immunotherapy: a step further towards precision medicine for glioblastoma. Molecules. 2020;25:490. https:\/\/doi.org\/10.3390\/molecules25030490.","journal-title":"Molecules"},{"key":"394_CR147","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41563-018-0147-9","volume":"17","author":"H Wang","year":"2018","unstructured":"Wang H, Mooney DJ. Biomaterial-assisted targeted modulation of immune cells in cancer treatment. Nat Mater. 2018;17:761\u201372. https:\/\/doi.org\/10.1038\/s41563-018-0147-9.","journal-title":"Nat Mater"},{"key":"394_CR148","doi-asserted-by":"publisher","unstructured":"Hheidari A, Mohammadi J, Ghodousi M, Mahmoodi M, Ebrahimi S, Pishbin E, et al. Metal-based nanoparticle in cancer treatment: lessons learned and challenges. Front Bioeng Biotechnol. 2024;12. https:\/\/doi.org\/10.3389\/fbioe.2024.1436297.","DOI":"10.3389\/fbioe.2024.1436297"},{"key":"394_CR149","doi-asserted-by":"publisher","unstructured":"Qiu J, Wu C. Smart nanoparticle delivery of cancer vaccines enhances tumor immune responses: a review. Front Nanatechnol. 2025;7. https:\/\/doi.org\/10.3389\/fnano.2025.1564267.","DOI":"10.3389\/fnano.2025.1564267"},{"key":"394_CR150","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12935-022-02687-8","volume":"22","author":"HE Marei","year":"2022","unstructured":"Marei HE. Multimodal targeting of glioma with functionalized nanoparticles. Cancer Cell Int. 2022;22:265. https:\/\/doi.org\/10.1186\/s12935-022-02687-8.","journal-title":"Cancer Cell Int"},{"key":"394_CR151","doi-asserted-by":"publisher","first-page":"114619","DOI":"10.1016\/j.addr.2022.114619","volume":"191","author":"H-J Liu","year":"2022","unstructured":"Liu H-J, Xu P. Strategies to overcome\/penetrate the BBB for systemic nanoparticle delivery to the brain\/brain tumor. Adv Drug Deliv Rev. 2022;191:114619. https:\/\/doi.org\/10.1016\/j.addr.2022.114619.","journal-title":"Adv Drug Deliv Rev"},{"key":"394_CR152","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12951-024-02311-z","volume":"22","author":"Z Sun","year":"2024","unstructured":"Sun Z, Zhao H, Ma L, Shi Y, Ji M, Sun X, et al. The quest for nanoparticle-powered vaccines in cancer immunotherapy. J Nanobiotechnol. 2024;22:61. https:\/\/doi.org\/10.1186\/s12951-024-02311-z.","journal-title":"J Nanobiotechnol"},{"key":"394_CR153","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.1039\/C9NR08958F","volume":"12","author":"P Lung","year":"2020","unstructured":"Lung P, Yang J, Li Q. Nanoparticle formulated vaccines: opportunities and challenges. Nanoscale. 2020;12:5746\u201363. https:\/\/doi.org\/10.1039\/C9NR08958F.","journal-title":"Nanoscale"},{"key":"394_CR154","doi-asserted-by":"publisher","unstructured":"Zhang W, Mehta A, Tong Z, Esser L, Voelcker NH. Development of polymeric nanoparticles for blood\u2013brain barrier transfer\u2014strategies and challenges. Adv Sci. 2021;8. https:\/\/doi.org\/10.1002\/advs.202003937.","DOI":"10.1002\/advs.202003937"},{"key":"394_CR155","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2174\/1381612822666161026162347","volume":"23","author":"DR Nogueira-Librelotto","year":"2017","unstructured":"Nogueira-Librelotto DR, Codevilla CF, Farooqi A, Rolim CMB. Transferrin-conjugated nanocarriers as active-targeted drug delivery platforms for cancer therapy. Curr Pharm Des. 2017;23:454\u201366. https:\/\/doi.org\/10.2174\/1381612822666161026162347.","journal-title":"Curr Pharm Des"},{"key":"394_CR156","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3390\/pharmaceutics12121198","volume":"12","author":"S Paranthaman","year":"2020","unstructured":"Paranthaman S, Goravinahalli Shivananjegowda M, Mahadev M, Moin A, Hagalavadi Nanjappa S, Nanjaiyah ND, et al. Nanodelivery systems targeting epidermal growth factor receptors for glioma management. pharmaceutics. 2020;12:1198. https:\/\/doi.org\/10.3390\/pharmaceutics12121198.","journal-title":"Pharmaceutics"},{"key":"394_CR157","doi-asserted-by":"publisher","first-page":"311","DOI":"10.7150\/ntno.38954","volume":"3","author":"C Liu","year":"2019","unstructured":"Liu C, Zhao Z, Gao H, Rostami I, You Q, Jia X, et al. Enhanced blood-brain-barrier penetrability and tumor-targeting efficiency by peptide-functionalized poly(amidoamine) dendrimer for the therapy of gliomas. Nanotheranostics. 2019;3:311\u201330. https:\/\/doi.org\/10.7150\/ntno.38954.","journal-title":"Nanotheranostics"},{"key":"394_CR158","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.bioactmat.2023.02.016","volume":"26","author":"T Su","year":"2023","unstructured":"Su T, Liu X, Lin S, Cheng F, Zhu G. Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy. Bioact Mater. 2023;26:169\u201380. https:\/\/doi.org\/10.1016\/j.bioactmat.2023.02.016.","journal-title":"Bioact Mater"},{"key":"394_CR159","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.biomaterials.2016.09.034","volume":"112","author":"Y Wang","year":"2017","unstructured":"Wang Y, Lin Y-X, Qiao S-L, An H-W, Ma Y, Qiao Z-Y, et al. Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment. Biomaterials. 2017;112:153\u201363. https:\/\/doi.org\/10.1016\/j.biomaterials.2016.09.034.","journal-title":"Biomaterials"},{"key":"394_CR160","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1021\/acs.nanolett.9b03753","volume":"20","author":"S Li","year":"2020","unstructured":"Li S, Wang Q, Shen Y, Hassan M, Shen J, Jiang W, et al. Pseudoneutrophil cytokine sponges disrupt myeloid expansion and tumor trafficking to improve cancer immunotherapy. Nano Lett. 2020;20:242\u201351. https:\/\/doi.org\/10.1021\/acs.nanolett.9b03753.","journal-title":"Nano Lett"},{"key":"394_CR161","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jconrel.2018.05.018","volume":"281","author":"W Ou","year":"2018","unstructured":"Ou W, Thapa RK, Jiang L, Soe ZC, Gautam M, Chang J-H, et al. Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy. J Controlled Release. 2018;281:84\u201396. https:\/\/doi.org\/10.1016\/j.jconrel.2018.05.018.","journal-title":"J Controlled Release"},{"key":"394_CR162","doi-asserted-by":"publisher","first-page":"107998","DOI":"10.1016\/j.jddst.2026.107998","volume":"117","author":"S Ullah","year":"2026","unstructured":"Ullah S, Poo GV, Yan G, Xin S, Chunrui Q, Aziz khan A, et al. Nanocarrier-engineered therapeutics for glioblastoma: challenges and strategies for overcoming the blood-brain barrier. J Drug Deliv Sci Technol. 2026;117:107998. https:\/\/doi.org\/10.1016\/j.jddst.2026.107998.","journal-title":"J Drug Deliv Sci Technol"},{"key":"394_CR163","doi-asserted-by":"publisher","first-page":"5754","DOI":"10.1021\/acs.molpharmaceut.8b00908","volume":"15","author":"AM Sofias","year":"2018","unstructured":"Sofias AM, Andreassen T, Hak S. Nanoparticle ligand-decoration procedures affect in vivo interactions with immune cells. Mol Pharm. 2018;15:5754\u201361. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00908.","journal-title":"Mol Pharm"},{"key":"394_CR164","doi-asserted-by":"publisher","unstructured":"Li J, Chen C, Xia T. Understanding nanomaterial\u2013liver interactions to facilitate the development of safer nanoapplications. Adv Mater. 2022;34. https:\/\/doi.org\/10.1002\/adma.202106456.","DOI":"10.1002\/adma.202106456"},{"key":"394_CR165","doi-asserted-by":"publisher","unstructured":"Suresh VSR. Recent advances on renal toxicity of engineered nanoparticles-a review. J Toxicol Risk Assess. 2021;7. https:\/\/doi.org\/10.23937\/2572-4061.1510036.","DOI":"10.23937\/2572-4061.1510036"},{"key":"394_CR166","doi-asserted-by":"publisher","first-page":"13013","DOI":"10.3390\/ijms232113013","volume":"23","author":"B D\u0105browska-Bouta","year":"2022","unstructured":"D\u0105browska-Bouta B, Sulkowski G, Gewartowska M, Stru\u017cy\u0144ska L. Endoplasmic reticulum stress underlies nanosilver-induced neurotoxicity in immature rat brain. Int J Mol Sci. 2022;23:13013. https:\/\/doi.org\/10.3390\/ijms232113013.","journal-title":"Int J Mol Sci"},{"key":"394_CR167","doi-asserted-by":"publisher","first-page":"7187","DOI":"10.3390\/app11167187","volume":"11","author":"PV Hauser","year":"2021","unstructured":"Hauser PV, Chang H-M, Yanagawa N, Hamon M. Nanotechnology, nanomedicine, and the kidney. Appl Sci. 2021;11:7187. https:\/\/doi.org\/10.3390\/app11167187.","journal-title":"Appl Sci"},{"key":"394_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/9954443","volume":"2021","author":"C Egbuna","year":"2021","unstructured":"Egbuna C, Parmar VK, Jeevanandam J, Ezzat SM, Patrick-Iwuanyanwu KC, Adetunji CO, et al. Toxicity of nanoparticles in biomedical application: nanotoxicology. J Toxicol. 2021;2021:1\u201321. https:\/\/doi.org\/10.1155\/2021\/9954443.","journal-title":"J Toxicol"},{"key":"394_CR169","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1002\/mco2.327","volume":"4","author":"L Xuan","year":"2023","unstructured":"Xuan L, Ju Z, Skonieczna M, Zhou P-K, Huang R. Nanoparticles-induced potential toxicity on human health: applications, toxicity mechanisms, and evaluation models. MedComm (Beijing). 2023;4:e327. https:\/\/doi.org\/10.1002\/mco2.327.","journal-title":"MedComm (Beijing)"},{"key":"394_CR170","doi-asserted-by":"publisher","first-page":"100252","DOI":"10.1016\/j.jtemin.2025.100252","volume":"13","author":"R Kumar","year":"2025","unstructured":"Kumar R, Kumar A, Bhardwaj S, Sikarwar M, Sriwastaw S, Sharma G, et al. Nanotoxicity unveiled: evaluating exposure risks and assessing the impact of nanoparticles on human health. J Trace Elem Minerals. 2025;13:100252. https:\/\/doi.org\/10.1016\/j.jtemin.2025.100252.","journal-title":"J Trace Elem Minerals"},{"key":"394_CR171","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1186\/s12951-024-02901-x","volume":"22","author":"X Ma","year":"2024","unstructured":"Ma X, Tian Y, Yang R, Wang H, Allahou LW, Chang J, et al. Nanotechnology in healthcare, and its safety and environmental risks. J Nanobiotechnol. 2024;22:715. https:\/\/doi.org\/10.1186\/s12951-024-02901-x.","journal-title":"J Nanobiotechnol"},{"key":"394_CR172","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/jfb16010024","volume":"16","author":"N Parvin","year":"2025","unstructured":"Parvin N, Joo SW, Mandal TK. Biodegradable and stimuli-responsive nanomaterials for targeted drug delivery in autoimmune diseases. J Funct Biomater. 2025;16:24. https:\/\/doi.org\/10.3390\/jfb16010024.","journal-title":"J Funct Biomater"},{"key":"394_CR173","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3762\/bjnano.11.44","volume":"11","author":"L Soddu","year":"2020","unstructured":"Soddu L, Trinh DN, Dunne E, Kenny D, Bernardini G, Kokalari I, et al. Identification of physicochemical properties that modulate nanoparticle aggregation in blood. Beilstein J Nanotechnol. 2020;11:550\u201367. https:\/\/doi.org\/10.3762\/bjnano.11.44.","journal-title":"Beilstein J Nanotechnol"},{"key":"394_CR174","doi-asserted-by":"publisher","first-page":"355101","DOI":"10.1088\/1361-6528\/ac738b","volume":"33","author":"Q Bi","year":"2022","unstructured":"Bi Q, Li Y, Luo R, Chen H, Lv Y, Liu Z-X, et al. Pi-induced in-situ aggregation of sevelamer nanoparticles for vascular embolization. Nanotechnology. 2022;33:355101. https:\/\/doi.org\/10.1088\/1361-6528\/ac738b.","journal-title":"Nanotechnology"},{"key":"394_CR175","doi-asserted-by":"publisher","unstructured":"Nasrullah M, Meenakshi Sundaram DN, Claerhout J, Ha K, Demirkaya E, Uludag H. Nanoparticles and cytokine response. Front Bioeng Biotechnol. 2023;11. https:\/\/doi.org\/10.3389\/fbioe.2023.1243651.","DOI":"10.3389\/fbioe.2023.1243651"},{"key":"394_CR176","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2025.5789","volume":"67","author":"J-X Si","year":"2025","unstructured":"Si J-X, Liu Z-C, Gu F, Jin X, Ma Y-Y. Nanoparticle-based delivery systems for targeted therapy in brain tumors: progress, challenges and perspectives (Review). Int J Oncol. 2025;67:1\u201315. https:\/\/doi.org\/10.3892\/ijo.2025.5789.","journal-title":"Int J Oncol"},{"key":"394_CR177","doi-asserted-by":"publisher","unstructured":"Jordan Paradise. Regulating nanomedicine at the food and drug administration. AMA J Ethics. 2019;21. https:\/\/doi.org\/10.1001\/amajethics.2019.347. E347-355.","DOI":"10.1001\/amajethics.2019.347"},{"key":"394_CR178","doi-asserted-by":"publisher","first-page":"100353","DOI":"10.1016\/j.ijpx.2025.100353","volume":"10","author":"S Imani","year":"2025","unstructured":"Imani S, Moradi S, Faraj TA, Hassanpoor P, Musapour N, Najmaldin SK, et al. Nanoparticle technologies in precision oncology and personalized vaccine development: Challenges and advances. Int J Pharm X. 2025;10:100353. https:\/\/doi.org\/10.1016\/j.ijpx.2025.100353.","journal-title":"Int J Pharm X"},{"key":"394_CR179","doi-asserted-by":"publisher","unstructured":"Kumar A, Dixit S, Srinivasan K, Vincent MD. Personalized cancer vaccine design using AI-powered technologies. Front Immunol. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1357217.","DOI":"10.3389\/fimmu.2024.1357217"},{"key":"394_CR180","doi-asserted-by":"publisher","unstructured":"Bulashevska A, Nacsa Z, Lang F, Braun M, Machyna M, Diken M, et al. Artificial intelligence and neoantigens: paving the path for precision cancer immunotherapy. Front Immunol. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1394003.","DOI":"10.3389\/fimmu.2024.1394003"},{"key":"394_CR181","doi-asserted-by":"publisher","unstructured":"Zhang W-Y, Zheng X-L, Coghi PS, Chen J-H, Dong B-J, Fan X-X. Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines. Front Immunol. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1438030.","DOI":"10.3389\/fimmu.2024.1438030"},{"key":"394_CR182","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1016\/j.apsb.2021.02.007","volume":"11","author":"Z Xu","year":"2021","unstructured":"Xu Z, Wang X, Zeng S, Ren X, Yan Y, Gong Z. Applying artificial intelligence for cancer immunotherapy. Acta Pharm Sin B. 2021;11:3393\u2013405. https:\/\/doi.org\/10.1016\/j.apsb.2021.02.007.","journal-title":"Acta Pharm Sin B"},{"key":"394_CR183","doi-asserted-by":"publisher","unstructured":"Reiman D, Sha L, Ho I, Tan T, Lau D, Khan AA. Integrating RNA expression and visual features for immune infiltrate prediction. Biocomputing 2019. WORLD SCIENTIFIC; 2018. pp. 284\u201395. https:\/\/doi.org\/10.1142\/9789813279827_0026.","DOI":"10.1142\/9789813279827_0026"},{"key":"394_CR184","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12859-018-2561-z","volume":"20","author":"KM Boehm","year":"2019","unstructured":"Boehm KM, Bhinder B, Raja VJ, Dephoure N, Elemento O. Predicting peptide presentation by major histocompatibility complex class I: an improved machine learning approach to the immunopeptidome. BMC Bioinformatics. 2019;20:7. https:\/\/doi.org\/10.1186\/s12859-018-2561-z.","journal-title":"BMC Bioinformatics"},{"key":"394_CR185","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41541-025-01258-y","volume":"10","author":"F Villanueva-Flores","year":"2025","unstructured":"Villanueva-Flores F, Sanchez-Villamil JI, Garcia-Atutxa I. AI-driven epitope prediction: a systematic review, comparative analysis, and practical guide for vaccine development. NPJ Vaccines. 2025;10:207. https:\/\/doi.org\/10.1038\/s41541-025-01258-y.","journal-title":"NPJ Vaccines"},{"key":"394_CR186","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248\u201362. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.019.","journal-title":"Cell Rep"},{"key":"394_CR187","doi-asserted-by":"publisher","first-page":"216806","DOI":"10.1016\/j.ccr.2025.216806","volume":"541","author":"L Lu","year":"2025","unstructured":"Lu L, Yang M, Deng D, Shi X, Lovell JF, Jin H, Nanovaccines. Antigen selection, stabilization, adjuvantation, formulation, and evaluation. Coord Chem Rev. 2025;541:216806. https:\/\/doi.org\/10.1016\/j.ccr.2025.216806.","journal-title":"Coord Chem Rev"},{"key":"394_CR188","doi-asserted-by":"publisher","unstructured":"Cai Y, Chen R, Gao S, Li W, Liu Y, Su G et al. Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy. Front Oncol 2023;12. https:\/\/doi.org\/10.3389\/fonc.2022.1054231","DOI":"10.3389\/fonc.2022.1054231"},{"key":"394_CR189","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1158\/0008-5472.CAN-24-2553","volume":"85","author":"J Zeng","year":"2025","unstructured":"Zeng J, Lin Z, Zhang X, Zheng T, Xu H, Liu T. Leveraging artificial intelligence for neoantigen prediction. Cancer Res. 2025;85:2376\u201387. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-2553.","journal-title":"Cancer Res"},{"key":"394_CR190","doi-asserted-by":"publisher","first-page":"29","DOI":"10.6026\/973206300200029","volume":"20","author":"R Farzan","year":"2024","unstructured":"Farzan R. Artificial intelligence in Immuno-genetics. Bioinformation. 2024;20:29\u201335. https:\/\/doi.org\/10.6026\/973206300200029.","journal-title":"Bioinformation"},{"key":"394_CR191","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1001\/jamaoncol.2024.5356","volume":"11","author":"M Rakaee","year":"2025","unstructured":"Rakaee M, Tafavvoghi M, Ricciuti B, Alessi JV, Cortellini A, Citarella F, et al. Deep learning model for predicting immunotherapy response in advanced non\u2013small cell lung cancer. JAMA Oncol. 2025;11:109. https:\/\/doi.org\/10.1001\/jamaoncol.2024.5356.","journal-title":"JAMA Oncol"},{"key":"394_CR192","doi-asserted-by":"publisher","first-page":"217881","DOI":"10.1016\/j.canlet.2025.217881","volume":"630","author":"Q Wen","year":"2025","unstructured":"Wen Q, Qiu L, Qiu C, Che K, Zeng R, Wang X, et al. Artificial intelligence in predicting efficacy and toxicity of Immunotherapy: applications, challenges, and future directions. Cancer Lett. 2025;630:217881. https:\/\/doi.org\/10.1016\/j.canlet.2025.217881.","journal-title":"Cancer Lett"},{"key":"394_CR193","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/diseases13010024","volume":"13","author":"DB Olawade","year":"2025","unstructured":"Olawade DB, Clement David-Olawade A, Adereni T, Egbon E, Teke J, Boussios S. Integrating AI into cancer immunotherapy\u2014a narrative review. Curr Appl Future Dir Dis. 2025;13:24. https:\/\/doi.org\/10.3390\/diseases13010024.","journal-title":"Narrative Rev Curr Appl Future Dir Dis"},{"key":"394_CR194","doi-asserted-by":"publisher","unstructured":"Liu Z, Lin G, Yan Z, Li L, Wu X, Shi J, et al. Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.989275.","DOI":"10.3389\/fimmu.2022.989275"},{"key":"394_CR195","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41577-023-00835-3","volume":"23","author":"D Hudson","year":"2023","unstructured":"Hudson D, Fernandes RA, Basham M, Ogg G, Koohy H. Can we predict T cell specificity with digital biology and machine learning? Nat Rev Immunol. 2023;23:511\u201321. https:\/\/doi.org\/10.1038\/s41577-023-00835-3.","journal-title":"Nat Rev Immunol"},{"key":"394_CR196","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2217\/epi-2017-0140","volume":"10","author":"L Hopp","year":"2018","unstructured":"Hopp L, L\u00f6ffler-Wirth H, Galle J, Binder H. Combined som-portrayal of gene expression and DNA methylation landscapes disentangles modes of epigenetic regulation in glioblastoma. Epigenomics. 2018;10:745\u201364. https:\/\/doi.org\/10.2217\/epi-2017-0140.","journal-title":"Epigenomics"},{"key":"394_CR197","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12876-025-03884-1","volume":"25","author":"N Norouzkhani","year":"2025","unstructured":"Norouzkhani N, Mobaraki H, Varmazyar S, Zaboli H, Mohamadi Z, Nikeghbali G, et al. Artificial intelligence networks for assessing the prognosis of gastrointestinal cancer to immunotherapy based on genetic mutation features: a systematic review and meta-analysis. BMC Gastroenterol. 2025;25:310. https:\/\/doi.org\/10.1186\/s12876-025-03884-1.","journal-title":"BMC Gastroenterol"},{"key":"394_CR198","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz184","author":"X Su","year":"2019","unstructured":"Su X, Chen N, Sun H, Liu Y, Yang X, Wang W, et al. Automated machine learning based on radiomics features predicts H3 K27M mutation in midline gliomas of the brain. Neuro Oncol. 2019. https:\/\/doi.org\/10.1093\/neuonc\/noz184.","journal-title":"Neuro Oncol"},{"key":"394_CR199","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00401-014-1338-3","volume":"128","author":"S Venneti","year":"2014","unstructured":"Venneti S, Santi M, Felicella MM, Yarilin D, Phillips JJ, Sullivan LM, et al. A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas. Acta Neuropathol. 2014;128:743\u201353. https:\/\/doi.org\/10.1007\/s00401-014-1338-3.","journal-title":"Acta Neuropathol"},{"key":"394_CR200","doi-asserted-by":"publisher","unstructured":"Das KP, J C. Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: current progress and challenges. Front Med Technol. 2023;4. https:\/\/doi.org\/10.3389\/fmedt.2022.1067144.","DOI":"10.3389\/fmedt.2022.1067144"},{"key":"394_CR201","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/pharmaceutics16101328","volume":"16","author":"DR Serrano","year":"2024","unstructured":"Serrano DR, Luciano FC, Anaya BJ, Ongoren B, Kara A, Molina G, et al. Artificial Intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine. Pharmaceutics. 2024;16:1328. https:\/\/doi.org\/10.3390\/pharmaceutics16101328.","journal-title":"Pharmaceutics"},{"key":"394_CR202","doi-asserted-by":"publisher","first-page":"136643","DOI":"10.1016\/j.ijbiomac.2024.136643","volume":"282","author":"VS Asediya","year":"2024","unstructured":"Asediya VS, Anjaria PA, Mathakiya RA, Koringa PG, Nayak JB, Bisht D, et al. Vaccine development using artificial intelligence and machine learning: a review. Int J Biol Macromol. 2024;282:136643. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.136643.","journal-title":"Int J Biol Macromol"},{"key":"394_CR203","doi-asserted-by":"publisher","unstructured":"Bae H, Ji H, Konstantinov K, Sluyter R, Ariga K, Kim YH, et al. Artificial intelligence-driven nanoarchitectonics for smart targeted drug delivery. Adv Mater. 2025;37. https:\/\/doi.org\/10.1002\/adma.202510239.","DOI":"10.1002\/adma.202510239"},{"key":"394_CR204","doi-asserted-by":"publisher","first-page":"9990","DOI":"10.1038\/s41467-024-54265-3","volume":"15","author":"X Shan","year":"2024","unstructured":"Shan X, Cai Y, Zhu B, Zhou L, Sun X, Xu X, et al. Rational strategies for improving the efficiency of design and discovery of nanomedicines. Nat Commun. 2024;15:9990. https:\/\/doi.org\/10.1038\/s41467-024-54265-3.","journal-title":"Nat Commun"},{"key":"394_CR205","doi-asserted-by":"publisher","unstructured":"Wang Q, Liu Y, Li C, Xu B, Xu S, Liu B. Machine learning-enhanced nanoparticle design for precision cancer drug delivery. Adv Sci. 2025;12. https:\/\/doi.org\/10.1002\/advs.202503138.","DOI":"10.1002\/advs.202503138"},{"key":"394_CR206","doi-asserted-by":"publisher","first-page":"15844","DOI":"10.1038\/s41598-024-66897-y","volume":"14","author":"ETC Huang","year":"2024","unstructured":"Huang ETC, Yang J-S, Liao KYK, Tseng WCW, Lee CK, Gill M, et al. Predicting blood\u2013brain barrier permeability of molecules with a large language model and machine learning. Sci Rep. 2024;14:15844. https:\/\/doi.org\/10.1038\/s41598-024-66897-y.","journal-title":"Sci Rep"},{"key":"394_CR207","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12672-025-01821-y","volume":"16","author":"M Bhange","year":"2025","unstructured":"Bhange M, Telange D. Convergence of nanotechnology and artificial intelligence in the fight against liver cancer: a comprehensive review. Discover Oncol. 2025;16:77. https:\/\/doi.org\/10.1007\/s12672-025-01821-y.","journal-title":"Discover Oncol"},{"key":"394_CR208","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12668-026-02476-x","volume":"16","author":"NI Okafor","year":"2026","unstructured":"Okafor NI, Igbokwe N, Onohuean H, Faya M, Choonara YE. Artificial intelligence-driven development and characterization of nanomedicine. Bionanoscience. 2026;16:255. https:\/\/doi.org\/10.1007\/s12668-026-02476-x.","journal-title":"Bionanoscience"},{"key":"394_CR209","doi-asserted-by":"publisher","unstructured":"Sanli I, Ozkan G, Capanoglu E. Artificial intelligence in quality- and safety-driven food formulation: current applications and future potential. Food Control. 2026;112355. https:\/\/doi.org\/10.1016\/j.foodcont.2026.112355.","DOI":"10.1016\/j.foodcont.2026.112355"},{"key":"394_CR210","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1002\/jor.25491","volume":"41","author":"RA Lacinski","year":"2023","unstructured":"Lacinski RA, Markel JE, Pratt HG, Reinbeau RM, Stewart A, Santiago SP, et al. Optimizing the synthesis of interleukin-12\u2010loaded PLGA nanospheres (rmIL\u201012ns) via ultrasonication for treatment of metastatic osteosarcoma. J Orthop Res. 2023;41:1565\u201381. https:\/\/doi.org\/10.1002\/jor.25491.","journal-title":"J Orthop Res"},{"key":"394_CR211","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5152\/dir.2020.19279","volume":"26","author":"T Akinci D\u2019Antonoli","year":"2020","unstructured":"Akinci D\u2019Antonoli T. Ethical considerations for artificial intelligence: an overview of the current radiology landscape. Diagn Interventional Radiol. 2020;26:504\u201311. https:\/\/doi.org\/10.5152\/dir.2020.19279.","journal-title":"Diagn Interventional Radiol"},{"key":"394_CR212","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/vaccines13020126","volume":"13","author":"M Saleh","year":"2025","unstructured":"Saleh M, El-Moghazy A, Elgohary AH, Saber WIA, Helmy YA. Revolutionizing nanovaccines: a new era of immunization. Vaccines (Basel). 2025;13:126. https:\/\/doi.org\/10.3390\/vaccines13020126.","journal-title":"Vaccines (Basel)"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00394-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00394-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00394-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:02:21Z","timestamp":1787115741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00394-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":212,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["394"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00394-3","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"61"}}